Welcome to our dedicated page for Satellos Bioscience SEC filings (Ticker: MSCLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Satellos Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Satellos Bioscience's regulatory disclosures and financial reporting.
Satellos Bioscience Inc. is organizing a virtual key opinion leader event on February 24, 2026 at 3:30 p.m. ET to discuss its lead drug candidate SAT-3247 for Duchenne muscular dystrophy (DMD). Neuromuscular disease expert Dr. Kevin M. Flanigan will review the unmet need and current DMD treatment landscape alongside company management.
The event will cover SAT-3247’s mechanism as an oral small molecule targeting AAK1 to help restore muscle stem-cell signaling disrupted by loss of dystrophin in DMD. It will highlight results from a completed Phase 1a/b trial in healthy volunteers and adults with DMD and provide updates on ongoing Phase 2 studies, including the adult open-label TRAILHEAD study and the global randomized, placebo-controlled pediatric BASECAMP trial.
Satellos Bioscience Inc. is organizing a virtual key opinion leader event on February 24, 2026 at 3:30 p.m. ET to discuss its lead drug candidate SAT-3247 for Duchenne muscular dystrophy (DMD). Neuromuscular disease expert Dr. Kevin M. Flanigan will review the unmet need and current DMD treatment landscape alongside company management.
The event will cover SAT-3247’s mechanism as an oral small molecule targeting AAK1 to help restore muscle stem-cell signaling disrupted by loss of dystrophin in DMD. It will highlight results from a completed Phase 1a/b trial in healthy volunteers and adults with DMD and provide updates on ongoing Phase 2 studies, including the adult open-label TRAILHEAD study and the global randomized, placebo-controlled pediatric BASECAMP trial.
Satellos Bioscience Inc. completed a public equity offering of 5,168,019 common shares and pre-funded warrants to purchase 495,049 common shares, raising about US$57.2 million in gross proceeds. The common shares were priced at US$10.10 per share, with pre-funded warrants priced at US$10.09999 each.
The company’s common shares began trading on the Nasdaq Global Market under the symbol “MSLE” and remain listed on the Toronto Stock Exchange as “MSCL.” Satellos plans to use the net proceeds mainly to fund research and development, including advancing its SAT-3247 program and other discovery and pre-clinical initiatives, as well as for working capital and general corporate purposes.
Satellos Bioscience Inc. completed a public equity offering of 5,168,019 common shares and pre-funded warrants to purchase 495,049 common shares, raising about US$57.2 million in gross proceeds. The common shares were priced at US$10.10 per share, with pre-funded warrants priced at US$10.09999 each.
The company’s common shares began trading on the Nasdaq Global Market under the symbol “MSLE” and remain listed on the Toronto Stock Exchange as “MSCL.” Satellos plans to use the net proceeds mainly to fund research and development, including advancing its SAT-3247 program and other discovery and pre-clinical initiatives, as well as for working capital and general corporate purposes.
Satellos Bioscience Inc. reported dosing the first participant in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept Phase 2 pediatric study of its oral drug SAT-3247 for Duchenne muscular dystrophy.
The trial plans to enroll 51 ambulatory children with Duchenne aged 7 to 9 years. Primary endpoints focus on safety, tolerability and effects on muscle force, while secondary endpoints assess muscle quality, function and regeneration.
SAT-3247 is described as a first-of-its-kind small molecule that targets AAK1 to help restore muscle stem cell signaling disrupted in Duchenne, and is being developed as a potential disease-modifying, dystrophin-independent treatment initially for Duchenne muscular dystrophy.
Satellos Bioscience Inc. reported dosing the first participant in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept Phase 2 pediatric study of its oral drug SAT-3247 for Duchenne muscular dystrophy.
The trial plans to enroll 51 ambulatory children with Duchenne aged 7 to 9 years. Primary endpoints focus on safety, tolerability and effects on muscle force, while secondary endpoints assess muscle quality, function and regeneration.
SAT-3247 is described as a first-of-its-kind small molecule that targets AAK1 to help restore muscle stem cell signaling disrupted in Duchenne, and is being developed as a potential disease-modifying, dystrophin-independent treatment initially for Duchenne muscular dystrophy.
Satellos Bioscience Inc. is executing an underwritten equity financing under its cross-border shelf program. The company entered an underwriting agreement covering the sale of 4,455,445 common shares and pre-funded warrants to purchase up to 495,049 common shares, plus an option for underwriters to buy 742,574 additional shares. These securities are issued off a previously cleared Form F-10 and Canadian short-form base shelf prospectus allowing up to $150,000,000 of securities. The pre-funded warrants carry a nominal exercise price of CAD$0.00001 per share. The common shares, including those issuable on warrant exercise, are approved for listing on Nasdaq Global Market and the Toronto Stock Exchange, subject to customary conditions.